Drug Profile


Alternative Names: Galexos; JNJ-38733214-AAA; Olysio; R-494617; SMV; Sovriad; TMC-435; TMC-435350

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medivir AB
  • Developer Janssen Pharmaceutical KK; Janssen R&D Ireland; Medivir AB
  • Class 3-ring heterocyclic compounds; Antivirals; Cyclopropanes; Quinolines; Small molecules; Sulfonamides; Thiazoles
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in Hong Kong (PO, Capsule)
  • 07 Aug 2017 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive, Treatment-experienced) in Egypt (PO,capsule), because there were no recent reports on development identified
  • 06 May 2017 Efficacy data from four clinical studies in Hepatitis C presented at the Digestive Disease Week 2017 (DDW-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top